JANX - Cantor starts Janux at overweight cites TCE leadership position
2024-03-20 12:21:57 ET
More on Janux Therapeutics
- Janux Therapeutics: Yes There's New Data; No It's Not A Buy Here
- Trial Data Triggers Massive Rally In Janux Therapeutics
- Janux: Additional Opportunity With JANX007 Dosing Update In The 2nd Half Of 2024
- Janux Therapeutics GAAP EPS of -$0.25 beats by $0.16, revenue of $2.46M beats by $1.72M
- Janux Therapeutics prices stock and warrants offering to raise $296.5M